[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632281":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":52,"collaborators":11,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":11,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Qilu Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"QL2106 injection","EXPERIMENTAL",null,[13],"Drug: QL2106 injection",{"label":15,"type":16,"description":11,"interventionNames":17},"Tremfya®","ACTIVE_COMPARATOR",[18],"Drug: Tremfya®",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Administer QL2106 injection by subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.The recommended dose is 100 mg.",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Administer Tremfya® by subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.The recommended dose is 100 mg.",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Yu ling Shi, Doctor","CONTACT","021-36803000","shiyuling1973@126.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":11,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Jining No.1 People's Hospital","RECRUITING","Jining","Shandong","China","CN",{"type":42,"coordinates":43},"Point",[44,45],116.58139,35.405,{"lat":45,"lon":44},[48],{"name":49,"role":30,"phone":50,"phoneExt":11,"email":51},"Mei dong Shi, Doctor","186 7876 9757","shidongmei28@163.com",{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100632281","phase-3-a-phase-3-clinical-study-of-ql2106-injection-100632281",false,"NCT07511647","A Phase 3 Clinical Study of QL2106 Injection","A Multicenter, Randomized, Double-Blind, Parallel, Active-Controlled Phase 3 Clinical Study to Compare the Efficacy and Safety of QL2106 Injection to Tremfya® in Patients With Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention\n* Total body surface area (BSA) greater than or equal to (\\>=)10 percent (%) at screening and baseline\n* Total psoriasis area and severity index (PASI) \\>=12 at screening and baseline\n* Total investigator global assessment (IGA) \\>=3 at screening and baseline\n* Candidate for phototherapy or systemic treatment for plaque psoriasis\n\nExclusion Criteria:\n\n* Nonplaque form of psoriasis (for example \\[e.g.\\], erythrodermic, guttate, or pustular)\n* Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)","ALL","18 Years",{"count":64,"type":65},318,"ESTIMATED","INTERVENTIONAL",[68],"PHASE3","It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis. A total of 318 subjects are planned to be included and randomized at a ratio of 1:1 to receive QL2106 injection orTremfya®",[71],"Plaque Psoriasis","2026-06-03",{"date":74,"type":75},"2026-06-05","ACTUAL",{"date":77,"type":65},"2026-06-15",{"date":79,"type":65},"2028-02-28",{"name":5,"class":6},1]